News & Events
-
May 15, 2012
Which New Diagnostics for Tuberculosis, and When?
Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME, Evidence for Scale-up Group. Which New Diagnostics for Tuberculosis, and When? The Journal of Infectious Diseases. 2012 May 15;205 Suppl 2:S191–8.
-
May 15, 2012
Drug-Resistant Tuberculosis–Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs
Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O’Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. Drug-Resistant Tuberculosis–Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. The Journal of Infectious Diseases. 2012 May 15;205 Suppl 2:S228–40.
-
May 1, 2012
Renewed Focus on Tuberculosis Holds Promise for New Treatments
FDA approved rifampin for the treatment of tuberculosis (TB) in 1971, the same year Intel Corporation invented the first microprocessor. Since then, advances in computer technology have revolutionized the way people live and work. But no additional medications have been approved by FDA for the treatment of Mycobacterium tuberculosis infection—a problem that federal officials and... -
April 24, 2012
Tucson institute plays critical cancer role
Re: the April 19 article “Vast study advances breast cancer fight.” -
April 23, 2012
ACRO Testifies Before FDA on Clinical Trial Modernization
WASHINGTON–(BUSINESS WIRE)– The Association of Clinical Research Organizations (ACRO) today provided the FDA with a number of suggestions to improve the drug development process, highlighted by a call to appoint a Chief Innovation Officer within the agency. ACRO’s recommendations were included in testimony presented by Executive Director Doug Peddicord, Ph.D., at a public hearing titled...